Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2017

View Archived Issues

Molecular Partners updates pipeline progress

Novel antibody against TGF-beta1 shows efficacy without cardiotoxicity in fibrosis model

TP-0469711 demonstrates promising activity as a new therapeutic for hyperphosphatemia

EMA grants positive opinion for Ocrevus as treatment for patients with RMS or PPMS

Homology Medicines enters R&D collaboration with Novartis

EMA recommends Prevymis for marketing authorization

Theravance Biopharma and Mylan submit NDA in U.S. for revefenacin

Shire's Adynovi receives positive opinion in E.U.

IDX-1197 demonstrates efficacy in models of ovarian cancer

EMA committee backs approval of Jorveza as treatment for eosinophilic esophagitis

EMA confirms further restrictions on use of Zinbryta

QS-1189 inhibits tumor growth in preclinical cancer models

EMA grants orphan drug designation to Debio-1347

Rodin Therapeutics awarded grant from Michael J. Fox Foundation

Phase II data presented for MEDI-6012 in patients with coronary heart disease

PRD-125: a potent SOAT2 inhibitor ameliorates atherosclerosis in rabbits

EMA grants accelerated assessment to patisiran for hereditary ATTR amyloidosis

Akcea initiates phase II program with AKCEA-ANGPTL3-LRx in rare hyperlipidemias

OncBioMune reports new data from phase I ProscaVax study

Positive interim results for phase I trial of ISC-hpNSC in Parkinson's disease

Phase I results reported for Bristol-Myers Squibb candidate for autoimmune diseases

FDA approves digital medicine system Abilify Mycite

Spero Therapeutics identifies novel antibiotic potentiators

Shanghai Hansoh Biomedical, Jiangsu Hansoh Pharmaceutical Group patent IDO-1/TDO inhibitors

Merck & Co. and IOmet Pharma discover novel IDO-1/TDO inhibitors

Dana-Farber Cancer Institute presents anti-CDK9 and CDK8 proteolysis targeting chimera compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...